BD to merge biosciences and diagnostics unit with Waters in $17.5bn tax-free deal

How will Waters’ $17.5 billion reverse Morris Trust deal reshape the regulated diagnostics and bioanalytical testing market?

Waters Corporation (NYSE: WAT) announced on July 14, 2025, that it has entered into a definitive agreement to merge with Becton, Dickinson and Company’s (NYSE: BDX) Biosciences & Diagnostic Solutions business through a tax-efficient Reverse Morris Trust transaction valued at approximately $17.5 billion. The deal, once completed, will result in the formation of a life sciences and diagnostics giant with pro forma 2025 revenue of approximately $6.5 billion and adjusted EBITDA of $2 billion. Subject to regulatory and shareholder approvals, the transaction is expected to close by the end of Q1 2026.

The merged entity will operate under the Waters name and continue to trade on the New York Stock Exchange under the ticker symbol WAT. Waters will retain its corporate headquarters in Milford, Massachusetts, while maintaining a significant operational presence across BD’s biosciences and diagnostics locations.

The combination doubles Waters’ total addressable market to an estimated $40 billion and expands its reach into high-growth adjacencies, including bioseparations, bioanalytical characterization, and multiplex diagnostics. Over 70% of the merged entity’s revenue is expected to be recurring annually, while more than 50% of instrument revenue is projected to be cyclical within a five- to ten-year window.

What revenue synergies and recurring income streams are expected from the Waters–BD combination?

Waters and BD expect the combined organization to unlock approximately $345 million in annualized EBITDA synergies by 2030. This includes around $200 million in cost savings by year three and $290 million in revenue synergies by year five. These synergies will primarily come from streamlined manufacturing and SG&A optimization, as well as cross-selling and adjacent market expansion.

Waters’ CEO Udit Batra emphasized that the company’s execution model—including service plan attachment, e-commerce acceleration, and proactive instrument replacement—will now be scaled across BD’s diagnostic and cytometry assets. The goal is to expand access to regulated, high-volume diagnostics in areas like immunology, infectious disease, and large-molecule QA/QC.

Industry observers noted that combining Waters’ Empower informatics platform with BD’s flow cytometry and molecular diagnostics capabilities is likely to result in differentiated offerings that can support emerging bioanalytical workflows and complex assay menus. Analysts also pointed out that BD’s entrenched position in clinical diagnostics will accelerate Waters’ penetration into regulated lab environments, supported by robust service infrastructure and automation platforms.

How are markets and institutional investors reacting to the transaction structure and financial profile?

The deal structure—designed as a Reverse Morris Trust—allows BD to spin off its Biosciences & Diagnostic Solutions business, which will simultaneously merge into a Waters subsidiary. Upon completion, BD shareholders will own 39.2% of the combined entity, while existing Waters shareholders will retain 60.8% ownership. BD will also receive a pre-closing cash distribution of approximately $4 billion, with plans to use at least half for share repurchases and the remainder for debt repayment.

Waters will take on roughly $4 billion in additional debt as part of the transaction, resulting in a pro forma net-debt-to-adjusted EBITDA ratio of 2.3x. Despite strong forward-looking EBITDA generation and margin expansion potential, Waters’ stock fell between 9–12% in early trading following the announcement. Investors appear cautious over potential dilution and the risks associated with integrating BD’s assets.

Institutional sentiment remains cautiously optimistic. While near-term financial headwinds are acknowledged, analysts have underscored the long-term strategic logic and recurring revenue model. The combined entity is expected to deliver mid- to high single-digit revenue growth and mid-teens adjusted EPS growth annually through 2030. By the end of the decade, Waters projects total revenue of $9 billion and adjusted EBITDA of $3.3 billion, with operating margins expected to expand by 500 basis points to 32%.

What long-term impact could the merger have on diagnostics, flow cytometry, and regulated testing markets?

BD’s Biosciences segment is widely regarded as a market leader in flow cytometry, immunology research, and clinical cell analysis, serving both academic and clinical researchers with high-performance instruments and reagents. Its Diagnostic Solutions arm complements this by offering a deep portfolio across microbiology, cervical cancer screening, molecular diagnostics, and point-of-care testing platforms. These capabilities provide BD with a strong foothold in regulated diagnostic workflows, infectious disease surveillance, and decentralized healthcare delivery.

Waters, historically rooted in chromatography, mass spectrometry, and informatics platforms like Empower™, brings precision chemical analysis and downstream QA/QC strengths to the table. Through this merger, Waters gains access to upstream workflows and real-world clinical validation environments, transforming its portfolio from a specialized tools provider into a more comprehensive, end-to-end life sciences and diagnostics solutions player.

The addition of BD’s biosciences and diagnostic products will open significant commercial and operational adjacencies for Waters—including entry into high-throughput hospital labs, distributed diagnostic networks, and biologics manufacturing environments that require integrated analytical and regulatory-grade tools. Analysts believe this expanded reach will also enable Waters to better compete for government tenders, centralized procurement contracts, and R&D partnerships in translational medicine.

Waters executives view this merger as a pivotal strategic inflection point. By integrating Waters’ strengths in chemical separations and bioanalytical instrumentation with BD’s capabilities in clinical diagnostics and regulatory science, the combined company aims to address the full bioanalytical lifecycle—from early discovery to patient-level diagnostics. This could redefine how liquid chromatography-mass spectrometry (LC-MS) is applied in regulated diagnostic environments, enabling new menu expansion opportunities in multiplex testing, drug monitoring, and personalized medicine.

Moreover, with BD’s diagnostic business providing a well-established channel into hospital systems and public health labs, Waters is now better positioned to challenge traditional in-vitro diagnostics (IVD) players. The combined portfolio could accelerate the evolution of LC-MS from research labs into routine clinical workflows, supported by BD’s automation expertise, assay development infrastructure, and global installed base.

Under the leadership of Udit Batra, the merged company intends to allocate significant R&D and go-to-market resources to capitalize on bioanalytical workflows involving flow cytometry, liquid biopsy, and large-molecule QA/QC—segments expected to drive the next wave of innovation in both life sciences and regulated diagnostics.

What are the expected regulatory milestones and closing timeline for the Waters–BD merger?

The Boards of Directors at both Waters and BD have unanimously approved the deal. Subject to customary conditions and regulatory approvals, the merger is expected to close by the end of Q1 2026. Udit Batra will remain CEO of the combined company, while Amol Chaubal will continue as CFO. Up to two BD designees will join the Waters Board following the close.

For BD, the transaction allows it to sharpen its focus on core medical technology verticals while realizing $4 billion in liquidity. Executives reaffirmed BD’s commitment to innovation, balance sheet optimization, and shareholder returns.

Institutional investors will be watching closely for early indicators of integration efficiency and whether the combined company can execute on its aggressive synergy and margin expansion targets. If successful, this merger could establish Waters as a dominant force in life sciences instrumentation and diagnostics, significantly reshaping the landscape for regulated, high-volume testing platforms worldwide.